Loading clinical trials...

Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain | Clinical Trials | Clareo Health

UNKNOWNPHASE3

Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain

Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain: A Prospective, Randomized, Controlled, Multi-center, Phase III Trial

NCT04533243•Fujian Cancer Hospital

View on ClinicalTrials.gov

Summary

Opioid is recommended for moderate cancer pain in WHO 3-step analgesic ladder. Transdermal administration of the strong opioid fentanyl was originally developed for patients unable to swallow analgesics because of malignancies in the head and neck region or the gastrointestinal tract, painful lesions in the mouth, or periods of nausea, vomiting, or bowel obstruction. The EMA recognizes that in exceptional clinical circumstances, the 12 μg/h fentanyl patch could be considered. To our knowledge, there is not a phase III trial to explore the efficacy and safety of 12 μg/h fentanyl patch in opioid-naive patients with moderate cancer pain.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18 years old or more;
•2. ECOG PS ≤3 ;
•3. Opioid tolerance not moderate pain patients (4≤ NRS ≤6 on 11 points, 0 no pain, 10 most pain);
•4. No taking strong opioids for the last 30 days;
•5. Estimated life expectancy of at least 3 months;
•6. Ability to communicate effectively with the study personnel about the nature of their pain;
•7. Ability to complete a diary;
•8. Cancer pain is expected to be relatively stable and last for more than 48 hours;
•9. The patient understands the research process, agrees to participate in the trial, cooperates with the treatment and visit plan, and signs an informed consent form.

Exclusion Criteria

•1. Known allergy to any ingredient in both fentanyl and morphine;
•2. No cancer associated pain or the pain of unknown cause, such as osteoarthritis pain, acute abdominal pain;
•3. Primary tumors or metastases in the brain;
•4. An active skin disease that precluded application of the transdermal system;
•5. Anti-cancer therapy (radiotherapy, chemotherapy, targeted therapy, etc.) is used during the study period, and the treatment has an impact on the analgesic effect or adverse reactions of analgesic drugs;
•6. No bowel movement within 3 days before the screening period;
•7. The patient has contraindications to the use of opioids: such as respiratory depression; head damage; paralytic intestinal obstruction; acute abdomen; chronic obstructive airway disease; pulmonary heart disease; chronic bronchial asthma; hypercapnia;
•8. Used monoamine oxidase inhibitor within 1 week before randomization;
•9. Any abnormal laboratory test results with obvious clinical significance, such as creatinine value ≥ 2 times the high limit of the normal value or ALT or AST ≥ 2.5 times the high limit of the normal value (for patients with liver metastases can be relaxed to ≥ 5 times the high limit of the normal value) ;
•10. Patients with a history of drug abuse;
+3 more criteria

Key Dates

Start Date

September 1, 2020

Primary Completion Date

August 31, 2022

Completion Date

August 31, 2022

Last Updated

August 31, 2020

Enrollment

209

ESTIMATED participants

Conditions

Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive

Interventions

2.5ug/h transdermal fentanyl

DRUG

Oral immediate-released morphine

DRUG